Indian Journal of Hematology and Blood Transfusion最新文献

{"title":"Application of Multi-Department Cooperation, Intelligent Prevention, and Supervision to Reduce the Incidence of Central Line-Associated Bloodstream Infections","authors":"Chuanfang Wu, Fan Dai, Donghua Yang, Xin You, Chuang Tan","doi":"10.1007/s12288-024-01760-8","DOIUrl":"https://doi.org/10.1007/s12288-024-01760-8","url":null,"abstract":"<p>Central line-associated bloodstream infections (CLABSIs) can result in worse outcomes and high hospitalization cost for patients. This study aimed to assess the effectiveness of multi-department cooperation, intelligent prevention, and supervision (MDCIPS) in reducing the incidence of CLABSIs and improving the clinical outcomes of the patients. Key issues were identified through a literature review and survey on the status quo. A MDCIPS model was thus built. A total of 440 patients with indwelling central venous catheters (CVCs) were enrolled in the study. The control group (<i>n</i> = 219) received conventional infection-control managements, while the intervention group (<i>n</i> = 221) received MDCIPS interventions in addition to conventional infection-control managements. The number of CLABSIs patients, incidence of CLABSIs, average length of hospital stay, average total hospitalization cost, and disease outcomes were compared between the two groups. The intervention group had a significant reduction in the number and incidence of CLABSIs (0[0%] vs. 4[1.33%], <i>P</i> &lt; 0.05). Two of the four patients with CLABSIs in the control group died. The average length of hospital stay was significantly longer in the control group than the intervention group (17 days vs. 13 days, <i>P</i> &lt; 0.001). The average hospitalization cost in the control group was much higher than that in the intervention group (92.8 thousand yuan vs. 65.2 thousand yuan, <i>P</i> &lt; 0.001). Patient outcome was improved in the intervention group than the control group (<i>P</i> = 0.001). In summary, the MDCIPS model effectively reduces the incidence of CLABSIs, alleviates the patients’ economic burden, and improves the clinical outcomes of the patients.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"4 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140584260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ex-Vivo TCR αβ and CD19 Depleted Haploidentical Stem Cell Transplantation with CD45RO Memory T Cell Addback for CARD11 Deficiency","authors":"Sandip Bartakke, Prasad Iyer","doi":"10.1007/s12288-024-01749-3","DOIUrl":"https://doi.org/10.1007/s12288-024-01749-3","url":null,"abstract":"","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"124 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140584079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India","authors":"Durba Biswas, Debapriya Basu, Arijit Nag, Jeevan Kumar, Suvro Sankha Datta","doi":"10.1007/s12288-024-01763-5","DOIUrl":"https://doi.org/10.1007/s12288-024-01763-5","url":null,"abstract":"<p>The aim of this study is to analyze the profile of patients receiving daratumumab and their presentation to the transfusion laboratory by looking at the different pre-transfusion policies and the risk of erythrocyte alloimmunization. Patients receiving daratumumab from 2018 to 2023 were reviewed. They were divided into two groups: Group I, presented before administration of daratumumab, and Group II, presented after drug administration. Appropriate strategies were applied to mitigate the drug interference, and the transfusion outcome was analyzed by following up with the patients for six months. A total of 48 patients were studied. The antibody screen was negative in patients who presented before the administration of daratumumab (n = 35). Extended phenotyping was done for 31 patients. Blood group genotyping was done for 4 patients. The patients who presented after daratumumab administration (n = 13) had a positive antibody screen that became negative with dithiothreitol-treated cells. A total of 261 red cell units were transfused to these patients (mean 5.55 units per patient). None of the patients developed antibodies during the follow-up period. The transfusion services must frame policies and protocols to mitigate drug interference. Good communication between transfusion services and clinical hematologists is a must to ensure safe transfusions.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"9 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140584008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palmoplantar Keratoderma in a Patient of Chronic Myeloid Leukemia on Dasatinib","authors":"Priyansh Gupta, Priyanka Sangwan, Prabodha Kumar Das, Madhusmita Sethy, Biswanath Behera, Vishal Thakur","doi":"10.1007/s12288-024-01754-6","DOIUrl":"https://doi.org/10.1007/s12288-024-01754-6","url":null,"abstract":"","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"46 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140584117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prothrombin G20210A Mutation is Rare but not Absent Among North Indian Patients with Thromboembolic Events","authors":"","doi":"10.1007/s12288-024-01741-x","DOIUrl":"https://doi.org/10.1007/s12288-024-01741-x","url":null,"abstract":"<h3>Abstract</h3> <p>Traditionally considered to be absent in India, prothrombin gene G20210A (NM_000506.5(F2): c.*97G &gt; A) mutation (PGM) has recently been reported in few Indian patients. We aimed to assess the prevalence of PGM in patients with thromboembolic events from north India region. The thrombophilia workup comprising Protein C, Protein S, Antithrombin functional activity, lupus anticoagulant and anti-ACA and anti-ß2GP1 antibodies were performed in coagulation analyzer (ACLTOP-500, Instrumentation Laboratory, USA) and automated chemiluminescent assay analyzer (ACUSTAR, IL) respectively. PCR–RFLP was used to perform PGM and FVL mutation. Out of 509 patients, DVT and CVT/CSVT were identified in 208 and 250 patients respectively. A total of 42 (8.2%) cases showed inherited thrombophilia and 11 (2.1%) acquired thrombophilia. Among the inherited defects, the most common was FVL mutation 31 (6%) The PGM was seen in only 2/509 (0.3%) patients. The prevalence of PGM in North Indian patients with DVT, stroke and CVT is 0.41% (2/509). Although PGM is rare in this population, its presence emphasizes its association with these conditions. However, the role of PGM testing remains debatable due to its scarcity among North Indians.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"1 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140301087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Halofuginone Inhibits Osteoclastogenesis and Enhances Osteoblastogenesis by Regulating Th17/Treg Cell Balance in Multiple Myeloma Mice with Bone Lesions","authors":"Xiaofei Wu, Qiong Sun, Xiang Li, Lin Jiang, Li Chen","doi":"10.1007/s12288-024-01756-4","DOIUrl":"https://doi.org/10.1007/s12288-024-01756-4","url":null,"abstract":"<p>Evidences shows that T helper 17 (Th17) and regulatory T (Treg) cells imbalance plays a critical role in bone lesions of MM patients. Therefore, regulating the Th17/Treg imbalance may be beneficial for bone lesions in MM. Ten MM mice complicated with bone lesions were established and divided into the halofuginone (HF) group and the PBS group. After treatment, tibia and fibula from both groups were scanned by micro-CT. Osteoclasts and osteoblasts were validated by histochemical staining and ELISA. Th17 and Treg cells were tested by flow cytometry. The correlations between Th17/Treg cell ratio and osteoclasts, osteoblasts and bone remodeling were analyzed using the Spearman relative analysis. After treatment, mice in the HF group had an increase in trabecular bone volume fraction and thickened cortex, but a decrease in trabecular separation compared to mice in the PBS group.Tartrate-resistant acid phosphase (TRAP) + osteoclasts and its biomarker TRACP5b in serum were reduced, while alkaline phosphatase (ALP) + osteoblasts and its biomarker N-terminal propeptide of type 1precollagen (P1NP) in serum were accreted in the HF group. Th17/Treg cell ratio in halofuginone-treated mice was 0.85 ± 0.05, and was significantly lower than that in PBS-treated mice, which was 1.51 ± 0.03. In addition, it showed that the Th17/Treg cell ratio was significantly and positively associated with osteoclasts, but was significantly and negatively associated with osteoblasts and bone remodeling. Halofuginone plays a critical role in the amelioration bone lesions in MM, as it can inhibit osteoclastogenesis and enhance osteoblastogenesis by regulating the Th17/Treg cell balance.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"32 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140301099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unmasking Infection Risks in Multiple Myeloma: Insights from a Retrospective Analysis","authors":"Linu Abraham Jacob, Sabeena K. Choudhary, M. C. Suresh Babu, Lokesh K N, A. H. Rudresha, L. K. Rajeev, Smitha C. Saldanha, Anup Hegde, Vivek B M","doi":"10.1007/s12288-024-01753-7","DOIUrl":"https://doi.org/10.1007/s12288-024-01753-7","url":null,"abstract":"<p>Multiple myeloma (MM) has witnessed significant therapeutic advancements through the introduction of proteasome inhibitors and immunomodulators, leading to improved treatment outcomes. However, infections remain a formidable challenge for MM patients. The objective of our research is to investigate the factors that can forecast infection risk in MM patients. In pursuit of this, we conducted a thorough retrospective examination of medical records from Kidwai Memorial Institute of Oncology, Bangalore, involving 145 MM patients. Out of the 145 patients analyzed, almost half (47.5%; <i>n</i> = 69) encountered at least one infection during the course of their disease. Respiratory-related infections were the most prevalent (76.2%), followed by urinary tract infections (10%) and instances of diarrhea (8.8%). Notably, gram-positive bacteria constituted the majority of identified causative organisms, accounting for 48.2% of isolated pathogens, while gram-negative bacteria comprised 37.9% of the isolated organisms. Most infections were observed either at the time of presentation or during the first month (40.5%). Overall mortality during the study period was 4.8% (<i>n</i> = 7). Infections contributed to 57.1% (<i>n</i> = 4 out of 7 deaths) of the mortality. Moreover, patients in advanced stages exhibited an elevated risk of infection at presentation. Infections remain a major cause of morbidity and mortality in patients with MM. Nearly half of MM patients experience an episode of infection during treatment.Gram-positive bacteria are the most common pathogens, with respiratory infections being the most common foci. Prompt identification and treatment of infections is essential, but can be challenging due to atypical or absent symptoms. Antibacterial prophylaxis is an important preventive strategy, but further research is needed to develop innovative approaches to infection prevention and targeted therapeutic interventions. We must strive to develop innovative approaches to infection prevention in MM patients. Also we need to advance our understanding of the interplay between infections and MM to improve quality of care and outcomes for these individuals. By addressing these challenges, we can aspire to offer MM patients a brighter and healthier future.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"21 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140301094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes and Determinants of Survival in Patients with Hematologic Malignancies Admitted to Intensive Care Units with Critical Illness","authors":"Suvir Singh, Rintu Sharma, Jagdeep Singh, Kunal Jain, Gurkirat Kaur, Vivek Gupta, P. L. Gautam","doi":"10.1007/s12288-024-01757-3","DOIUrl":"https://doi.org/10.1007/s12288-024-01757-3","url":null,"abstract":"<p>Outcomes of patients with hematologic malignancies requiring ICU care for critical illness are suboptimal and represent a major unmet need in this population. We present data from a dedicated haematology oncology setting including 63 patients with a median age of 60 years admitted to the ICU for critical illness with organ dysfunction. The most common underlying diagnosis was multiple myeloma (30%) followed by acute myeloid leukemia (25%). Chemotherapy had been initiated for 90.7% patients before ICU admission. The most common indication for ICU care was respiratory failure (36.5%) and shock (17.5%) patients. Evidence of sepsis was present in 44 (69%) patients. After shifting to ICU, 32 (50%) patients required inotropic support and 18 (28%) required invasive mechanical ventilation. After a median of 5 days of ICU stay, 43.1% patients had died, most commonly due to multiorgan dysfunction. Risk of mortality was higher with involvement of more than two major organs (<i>p</i> = .001), underlying AML (<i>p</i> = .001), need for mechanical ventilation (<i>p</i> = .001) and high inotrope usage (<i>p</i> = .004). Neutropenia was not associated with mortality. Our study indicates high rates of short term mortality and defines prognostic factors which can be used to prognosticate patients and establish goals of care.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"24 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140301302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CANCER Care in COVID-19 ERA: A Prospective Survey to Study the Preferences and Perspectives of Patients with Hematological Malignancies in a Tertiary Cancer Care Setting in India","authors":"Surabhi Bhat, Avinash Bonda, Manju Sengar, Jayashree Thorat, Bhausaheb Bagal, Lingaraj Nayak, Jayita Deodhar, Karthik Rengaraj, Neha Sharma, Sadhana Kannan, Hemanth Muthuluri, Smruti Mokal, Thomas Eipe, Hasmukh Jain","doi":"10.1007/s12288-024-01750-w","DOIUrl":"https://doi.org/10.1007/s12288-024-01750-w","url":null,"abstract":"","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"24 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140197553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transient Spontaneous Remission of Acute Myeloid Leukemia with Mutated RUNX1: A Rare Report","authors":"Xue Wu, Jingyuan Zhao, Yingying Chen, Zhihua Zhang, Xinhong Yang","doi":"10.1007/s12288-024-01758-2","DOIUrl":"https://doi.org/10.1007/s12288-024-01758-2","url":null,"abstract":"","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"28 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140197351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}